7Baggers
Quarterly
Annual
    Unit: USD2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 
      
    		                                 
      operating activities
    		                                 
      net income
    		-20,004,000 -24,281,000 -15,714,000 -16,808,000 -18,090,000 -21,952,000 -16,962,000 -16,481,000 -22,786,000 -16,902,000 -15,031,000 -19,864,000 13,138,000 -38,774,000 -30,139,000 -42,194,000 -38,102,000 -11,349,000 -21,668,000 -18,367,000 -21,050,000  -23,126,000 -13,436,000 -13,005,000  -7,922,000 -8,569,000 -8,294,000 -11,863,000 -15,445,000 -15,377,000 -15,180,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                 
      depreciation
    		5,000 22,000 30,000 29,000 30,000 29,000 30,000 30,000 30,000 65,000 81,000 81,000 261,000 94,000 108,000 114,000 113,000 104,000 100,000 667,000 125,000  138,000 144,000 146,000         
      amortization of right-of-use asset and lease liability
    		             27,000 42,000 55,000 57,000                 
      stock-based compensation expense
    		1,517,000 1,432,000 1,313,000 1,287,000 1,356,000 1,758,000 1,646,000 1,574,000 1,987,000 2,170,000 1,980,000 2,933,000 2,156,000 1,311,000 1,915,000 3,065,000 2,248,000 1,763,000 2,041,000 1,539,000 1,328,000  1,660,000 1,213,000 1,197,000  1,307,000 1,727,000 1,706,000 2,039,000 2,375,000 2,537,000 3,134,000 
      amortization of deferred financing costs, debt discounts and premiums and discounts on available-for-sale marketable securities
    		             2,705,000 1,611,000 1,207,000 1,608,000 1,479,000 157,000 95,000 83,000  65,000 59,000 46,000         
      change in fair value of preferred stock tranche liability
    		                                 
      changes in operating assets and liabilities:
    		                                 
      accounts receivable
    		             -321,000 -814,000 -831,000 -252,000 10,256,000                
      prepaid expenses, other current assets and other assets
    		-1,442,000 581,000 -2,089,000 -605,000 -262,000 1,101,000 510,000 276,000 912,000 -932,000 -1,814,000 -450,000 3,903,000 223,000 -666,000 660,000 -1,094,000 -22,000 -688,000 237,000 -694,000  908,000 -387,000 -1,092,000         
      accounts payable
    		639,000 -424,000 2,000 -458,000 3,653,000 -688,000 92,000 1,661,000 -754,000 -1,058,000 774,000 -3,002,000 2,440,000 813,000 -2,689,000 2,938,000 -1,660,000 -1,060,000 3,544,000 642,000 -2,078,000  538,000 -1,864,000 4,594,000  -148,000 -485,000 -1,347,000 303,000   891,000 
      accrued expenses and other liabilities
    		2,970,000 -594,000 -1,045,000 195,000 -2,870,000 4,486,000 -2,449,000 3,410,000 1,490,000 1,922,000 -5,026,000 -8,950,000 1,639,000 -1,714,000 2,206,000 -88,000 -2,111,000 4,501,000 4,616,000 4,920,000 -135,000  7,967,000 -210,000 -2,538,000  440,000 205,000 -2,613,000 -1,116,000 654,000   
      deferred liabilities
    		291,000 -659,000 693,000                               
      other long-term liabilities
    		             0                    
      net cash from operating activities
    		-16,589,000 -19,904,000 -20,286,000 -16,616,000 -15,082,000 -12,694,000 -19,281,000 -9,933,000 -10,827,000 -13,424,000 -19,318,000 -21,703,000 44,747,000 -37,221,000 -27,848,000 -34,669,000 -38,780,000 -19,188,000 -22,560,000 -10,313,000 -22,454,000  -11,850,000 -14,481,000 -10,652,000  -6,019,000 -6,691,000 -10,822,000     
      capex
    		0 0 0 0 0 0 0 0 0 0 -196,000 0 205,000 0 0 0 0 -263,000 -567,000 -217,000 67,000  0 0 0  0 0 0     
      free cash flows
    		-16,589,000 -19,904,000 -20,286,000 -16,616,000 -15,082,000 -12,694,000 -19,281,000 -9,933,000 -10,827,000 -13,424,000 -19,514,000 -21,703,000 44,952,000 -37,221,000 -27,848,000 -34,669,000 -38,780,000 -19,451,000 -23,127,000 -10,530,000 -22,387,000  -11,850,000 -14,481,000 -10,652,000  -6,019,000 -6,691,000 -10,822,000     
      investing activities
    		                                 
      purchases of investments
    		-70,079,000 0 -13,804,000 -2,475,000 -10,353,000 -1,000 -4,986,000 -33,184,000 0 -35,707,000 -17,551,000   -20,937,000 -35,549,000 0 -37,637,000 -110,540,000     0 0 -6,461,000  -19,823,000 -4,052,000 -36,346,000     
      maturities of investments
    		0 14,000,000 13,000,000 15,500,000 15,000,000 29,250,000 24,250,000 33,250,000 10,000,000 38,100,000 5,375,000 0 0 46,063,000 53,150,000 46,530,000 38,000,000 6,000,000 0 0 4,500,000  21,325,000 14,023,000 10,557,000  23,550,000 35,160,000 37,450,000 63,548,000 52,385,000 25,949,000 31,123,000 
      net cash from investing activities
    		-70,079,000 14,000,000 -804,000 13,025,000 4,647,000 29,249,000 19,264,000 66,000 10,000,000 2,393,000 -12,372,000 -79,380,000 -6,000 25,126,000 17,594,000 46,530,000 363,000 -126,803,000 -15,479,000 -530,000 4,435,000  21,325,000 14,023,000 4,096,000  3,729,000 31,108,000 1,104,000     
      financing activities
    		                                 
      proceeds from issuance of series b convertible preferred stock
    		                                 
      proceeds from long-term debt
    		                  0    0 0 2,386,000         
      proceeds from insurance premium financing
    		                                 
      payments on insurance premium financing
    		                                 
      proceeds from the exercise of stock options and employee stock purchase program
    		             0                    
      proceeds from the issuance of common stock and pre-funded warrants
    		-486,000                                 
      net cash from financing activities
    		-891,000 91,481,000 44,050,000 0 25,624,000 708,000 25,452,000 6,805,000 169,000 489,000 -578,000 -36,606,000 137,000 -12,704,000 494,000 9,694,000 75,000 145,469,000 74,000 115,320,000 299,000  14,212,000 -138,000 2,386,000     51,000 62,000 8,122,000 55,350,000 
      increase in cash, cash equivalents and restricted cash
    		-87,559,000 85,577,000 22,960,000 -3,591,000 15,189,000 17,263,000 25,435,000  -658,000 -10,542,000 -32,268,000 -137,689,000 44,878,000 -24,799,000 -9,760,000   -522,000 -37,965,000               
      cash, cash equivalents and restricted cash at beginning of period
    		0 0 75,789,000 0 0 0 21,493,000 0 0 0 68,023,000 0 0 0 0 0 130,608,000 0 0 0 82,338,000             
      cash, cash equivalents and restricted cash at end of period
    		-87,559,000 85,577,000 98,749,000 -3,591,000 15,189,000 17,263,000 46,928,000 -3,062,000 -658,000 -10,542,000 35,755,000 -137,689,000 44,878,000 -24,799,000 -9,760,000 21,555,000 92,266,000 -522,000 -37,965,000 104,477,000 64,618,000             
      supplemental disclosure of non-cash investing and financing activities
    		                                 
      issuance of preferred stock tranche liability
    		0                                 
      issuance costs included in accounts payable and accrued expenses
    		                                 
      proceeds from the issuance of common stock
    		                 0 -301,000 105,158,000 299,000             
      deferred financing costs included in accounts payable and accrued expenses
    		      624,000                           
      amortization of acquired intangible asset
    		           0 8,000 392,000 392,000 393,000 392,000                 
      loss on debt extinguishment
    		                                 
      change in fair value of interest make whole benefit from 2019 notes
    		                                 
      inventory
    		             -2,618,000 -184,000 12,000 21,000 -196,000                
      intangible assets & property, plant and equipment
    		                                 
      purchases of property and equipment
    		       0 0 0 -196,000 0 -6,000     -263,000 -567,000 -575,000 -102,000             
      repayment of long-term debt
    		                                 
      interest make-whole payments on the 2019 notes
    		                                 
      settlement of restricted stock for tax withholdings
    		                                 
      supplemental disclosure
    		                                 
      cash paid for interest
    		                                 
      common stock issuance costs included in accounts payable and accrued expenses
    		         0 15,000 0 -10,000 0 0 0 15,000 0 -301,000 281,000 35,000             
      conversion of 2019 notes into common stock
    		           0 0                     
      conversion of 2020 notes into common stock
    		       0                          
      purchases of property and equipment including in accounts payable and accrued expenses
    		                                 
      change in fair value of conversion option of 2020 notes on exchange
    		                                 
      settlement of restricted stock for tax withholdings included in accrued expenses
    		                                 
      payment of deferred offering costs
    		                                 
      deferred offering costs included in accounts payable and accrued expenses
    		                                 
      settlement of restricted stock units for tax withholdings included in accrued expenses
    		         9,000 9,000 711,000 42,000                     
      receivables related to stock option exercises in prepaid expenses and other current assets
    		          157,000                       
      proceeds from long-term debt, net of issuance costs
    		             -24,000 0                   
      repayment of long-term, debt
    		                                 
      principal payments on the 2019 notes
    		                                 
      decrease in cash, cash equivalents and restricted cash
    		                -38,342,000    -17,720,000             
      purchases of property and equipment included in accounts payable and accrued expenses
    		           0 211,000                     
      change in fair value of conversion option of notes on exchange
    		                                 
      change in fair value of interest make whole provision and conversion option for notes
    		                                 
      gain on sale of fixed assets
    		                 0 0 -46,000 -33,000             
      sales of property and equipment
    		                 0 0 45,000 37,000             
      acquisition of intangible asset
    		                                 
      proceeds from issuance of convertible senior notes, net of issuance costs
    		                                 
      principal payments on the convertible senior notes
    		                                 
      deferred debt financing costs
    		                      0           
      conversion of notes into common stock
    		                                 
      acquired intangible assets included in intangible assets, net and accrued expenses
    		                                 
      proceeds from the exercise of stock options
    		               0 75,000 172,000 375,000           0 4,000 2,000 7,000 
      purchases of property and equipment in accounts payable
    		                   358,000 169,000            8,000 
      change in fair value of conversion option for convertible senior notes
    		                                 
      cash used to settle restricted stock liability
    		                                 
      supplemental disclosure of non-cash financing activities
    		                                 
      amortization of acquired intangible assets
    		                                 
      supplemental disclosure of non-cash investing activities
    		                                 
      deferred financing costs in accounts payable and accrued expenses
    		                        140,000         
      net cash provided by:
    		                                 
      increase in cash and cash equivalents
    		                     30,906,000 23,687,000 -596,000 -4,170,000  -2,290,000       
      liability classified stock-based compensation awards
    		                          0 0 -69,000     
      decrease in restricted cash
    		                                 
      cash and cash equivalents at beginning of period
    		                      0 0 32,349,000  0 0 24,870,000 0 0 0 33,901,000 
      cash and cash equivalents at end of period
    		                      23,687,000 -596,000 28,179,000  -2,290,000 24,417,000 15,147,000 5,039,000 -15,341,000 5,047,000 30,125,000 
      net cash provided by
    		                                 
      net increase in cash and cash equivalents
    		                                 
      depreciation and amortization
    		                          159,000 176,000 183,000 188,000 189,000 189,000 188,000 
      amortization of premiums and discounts on available-for-sale marketable securities
    		                          -50,000 -80,000 -12,000    58,000 
      prepaid expenses and other current assets
    		                          195,000 335,000 -376,000     
      net proceeds from the issuance of common stock and restricted common stock
    		                                 
      decrease in cash and cash equivalents
    		                            -9,723,000     
      proceeds from the issuance of common stock included in prepaid expenses and other current assets
    		                                1,972,000 
      public offering costs in accounts payable and accrued expenses and other liabilities
    		                                55,000 
      non-cash expense related to purchase of technology rights
    		                                 
      loss on disposal of fixed assets
    		                                 
      changing in operating assets and liabilities:
    		                                 
      increase in restricted cash
    		                                 
      amortization of premiums and discounts on available for sale marketable securities
    		                              79,000   
      common stock issued to purchase technology rights
    		                                 
      net proceeds from the issuance of common stock
    		                                 
      cash used to settle restricted stock liability awards
    		                                 
      net proceeds from the sale of common stock
    		                               8,150,000 55,566,000 
      supplemental disclosure of non-cash financing and investing activities
    		                                 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.